The webinar began with a polling question, posed by Fisher Clinical expert Dan Ramos. I recently had the opportunity to sit in on a webinar held by Fisher Clinical Services. What Are The Biggest Biosimilar Blinding Challenges? But because of this aggressive timeline, it becomes more difficult to ensure that clinical trial personnel running biosimilar trials clearly understand their roles and responsibilities, especially when it comes to maintaining a blind. The obvious benefit is that this abbreviated clinical pathway gives a biosimilar candidate earlier access to the market. Unlike novel biologics, a biosimilar candidate has a shortened clinical development process involving only Phase 1 and Phase 3 trials.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |